Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 24 articles: HTML format

Single Articles

February 2024
1. WU M, Hanly A, Gibson F, Fisher R, et al
   The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
   J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
   PubMed     Abstract available
   
   
   December 2023
2. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
   Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
   J Clin Invest. 2023;133:e177489.
   PubMed    
   
   
   November 2023
3. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
   Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
   J Clin Invest. 2023;133:e167951.
   PubMed     Abstract available
   
   
   August 2023
4. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
   Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
   J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
   PubMed     Abstract available
   
   
   July 2023
5. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
   Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
   J Clin Invest. 2023;133:e170762.
   PubMed     Abstract available
   
   
   January 2023
6. HUUHTANEN J, Kasanen HH, Peltola K, Lonnberg T, et al
   Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.
   J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809.
   PubMed     Abstract available
   
   
   July 2022
7. HICKMAN A, Koetsier J, Kurtanich T, Nielsen MC, et al
   LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
   J Clin Invest. 2022;132.
   PubMed     Abstract available
   
   
   June 2022
8. HUANG H, Nie C, Liu XF, Song B, et al
   Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
   J Clin Invest. 2022 Jun 21. pii: 157726. doi: 10.1172/JCI157726.
   PubMed     Abstract available
   
   
   May 2022
9. PAL S, Perrien DS, Yumoto T, Faccio R, et al
   The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cells homing to bone.
   J Clin Invest. 2022 May 3. pii: 157340. doi: 10.1172/JCI157340.
   PubMed     Abstract available
   
   
   
10. PAGLIANO O, Morrison RM, Chauvin JM, Banerjee H, et al
    Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    April 2022
11. CHEN D, Le SB, Hutchinson TE, Calinescu AA, et al
    Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    January 2022
12. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    PubMed     Abstract available
    
    
    November 2021
13. KRISTENSEN NP, Heeke C, Tvingsholm SA, Borch A, et al
    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma.
    J Clin Invest. 2021 Nov 23. pii: 150535. doi: 10.1172/JCI150535.
    PubMed     Abstract available
    
    
    
14. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    October 2021
15. PERI A, Greenstein E, Alon M, Pai JA, et al
    Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
16. CHAKRABORTY B, Byemerwa J, Shepherd JH, Haines CN, et al
    Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    J Clin Invest. 2021 Oct 12. pii: 151347. doi: 10.1172/JCI151347.
    PubMed     Abstract available
    
    
    August 2021
17. VEATCH JR, Singhi N, Srivastava S, Szeto JL, et al
    A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    May 2021
18. GIBLIN W, Bringman-Rodenbarger L, Guo AH, Kumar S, et al
    The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
    J Clin Invest. 2021 May 4. pii: 138926. doi: 10.1172/JCI138926.
    PubMed     Abstract available
    
    
    April 2021
19. KIM YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, et al
    Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy.
    J Clin Invest. 2021 Apr 29. pii: 145859. doi: 10.1172/JCI145859.
    PubMed     Abstract available
    
    
    March 2021
20. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
21. HEEMSKERK N, Gruijs M, Temming AR, Heineke MH, et al
    Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
22. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.
    J Clin Invest. 2021 Mar 9. pii: 140752. doi: 10.1172/JCI140752.
    PubMed     Abstract available
    
    
    May 2020
23. LI J, Wang W, Zhang Y, Cieslik M, et al
    Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
    J Clin Invest. 2020;130:2712-2726.
    PubMed     Abstract available
    
    
    
24. THEIVANTHIRAN B, Evans KS, DeVito NC, Plebanek M, et al
    A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    J Clin Invest. 2020;130:2570-2586.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.